Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822613 · ClinicalTrials.gov registry record · Phase 1
Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01822613 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT01822613, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Irinotecan
- DRUG BYL719
- DRUG LJM716
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-07-26 |
| Est. Completion | 2016-06-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822613
The ClinicalTrials.gov registry entry for NCT01822613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT01822613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822613 about?
NCT01822613 is a clinical study titled "Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)". To study the safety and efficacy of the combination of LJM716 and BYL719 against currently available treatments of physician's choice in previously treated esophageal squamous cell carcinoma patients.
What is the current status of trial NCT01822613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-07-26. Estimated completion is 2016-06-03.
What interventions are being tested in trial NCT01822613?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Irinotecan (DRUG), BYL719 (DRUG), LJM716 (DRUG).
Who is sponsoring clinical trial NCT01822613?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.